AR-V7 Key in Tx of mCRPC

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.

In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.

Recent Videos
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Related Content
Radiotherapy is a very evidence-based subject. We can tell quite accurately how well we think [a patient] is going to do.

How Has Radiotherapy Advanced in Cancer Treatment?

Tim Cortese
October 11th 2025
Article

Compared with 25 years ago, radiotherapy is much more personalized and targeted, thus reducing the strain on patients with cancer.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

Russ Conroy
October 3rd 2025
Article

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.

Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

Tim Cortese
October 1st 2025
Article

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Ariana Pelosci
September 30th 2025
Article

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.